Attenuation Effects of Bulk and Nanosized ZnO on Glucose, Lipid Level, and Inflammation Profile in Obese Mice.


School of Food and Biological Engineering, Hefei University of Technology, Hefei, 230009, China. [Email]


ZnO and ZnO nanoparticles (ZnO NPs) are widely used in food packaging, food preservation, cosmetic preparation, and animal feed. ZnO is alleged showing multiple bioactivities including antimicrobial and anti-inflammation. It is hypothesized in this study that bulk ZnO and ZnO NPs could attenuate symptoms associated with high-fat-diet-induced obesity. Bulk ZnO and ZnO NPs with diameters of 30 and 90 nm were administered to high-fat-diet (HFD)-induced obese mice. Body weight, liver and fat tissue indices of ZnO-treated mice were decreased compared with those of obese mice (MOD). Blood glucose levels in oral glucose tolerant test and insulin tolerant test of ZnO-treated mice were lower than those of MOD. Serum lipid profile of ZnO-treated mice was ameliorated with lower total cholesterol, total triglyceride, and low-density lipoprotein cholesterol levels compared with that of MOD. In addition, the levels of serum IL-1β and LPS-binding protein were also decreased by ZnO treatment. Both bulk and nanosized ZnO could attenuate HFD-induced phenotypes related with obesity, but ZnO NP is more efficient to lower the fat index and bulk ZnO is better to restore the disturbed serum lipid profile.


Glucose level,Inflammation,Insulin resistant,Lipid profile,Zinc supplement,

OUR Recent Articles